XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Related Parties Transactions (Tables)
 6 Months Ended
Jun. 30, 2024
Related Parties Transactions [Abstract]  
Schedule of Related Parties of the Company with whom Transactions The related parties of the Company with whom transactions are reported in these financial statements are as follows:
Name of entity or Individual   Relationship with the Company and its subsidiaries
BioFirst Corporation (the “BioFirst”)   Entity controlled by controlling beneficiary shareholder of YuanGene
BioFirst (Australia) Pty Ltd. (the “BioFirst (Australia)”)   100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene
Rgene Corporation (the “Rgene”)   Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene; the Chairman of Rgene is Mr. Tsung-Shann Jiang
ForSeeCon Corporation (the “FEYE”)   Cost method investment
YuanGene Corporation (the “YuanGene”)   Controlling beneficiary shareholder of the Company
GenePharm Inc. (the “GenePharm”)   Dr. George Lee, Board Director of BioKey, is the Chairman of GenePharm.
The Jiangs   Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company; the Chairman of Rgene; the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst

Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang’s wife,  and a member of board of directors of BioLite Inc.

Mr. Eugene Jiang is Mr. and Ms. Jiang’s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.

Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang’s sibling and the director of the Company.

Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang’s sibling.
BioLite Japan   Entity controlled by controlling beneficiary shareholder of ABVC
BioHopeKing Corporation (“BHK”)   Entity controlled by controlling beneficiary shareholder of ABVC
Schedule of Pursuant Licensing Agreement Related Amendment During the six months ended June 30, 2024, the Company received $116,000 pursuant to the licensing agreement and related amendment with FEYE, and recognized $116,000 revenue in the period ended June 30, 2024. Please refer to Note 4, Collaborative Agreements for details.
   June 30,   June 30, 
   2024   2023 
   (Unaudited)     
FEYE  $116,000   $
   -
 
Total  $116,000   $
-
 
Schedule of Accounts Receivable Due From Related Parties Accounts receivable due from related parties consisted of the following as of the periods indicated:
   June 30,   December 31, 
   2024   2023 
   (Unaudited)     
Rgene  $10,463   $10,463 
Total  $10,463   $10,463 

 
Schedule of Due From Related Parties - Current Due from related-party - Current
   June 30,   December 31, 
   2024   2023 
   (Unaudited)     
Rgene  $553,229   $541,486 
BioFirst   705,083    206,087 
Total  $1,258,312   $747,573 
Schedule of Due From Related Parties - Non Current Due from related parties - Non-Current
   June 30,   December 31, 
   2024   2023 
BioFirst (Australia)  $839,983   $839,983 
BioHopeKing Corporation   121,392    113,516 
Total   961,375    953,499 
Less: allowance for expected credit losses accounts   (839,983)   (839,983)
Net  $121,392   $113,516 
Schedule of Amount Due to Related Parties Amount due to related parties consisted of the following as of the periods indicated:
   June 30,   December 31, 
   2024   2023 
   (Unaudited)     
The Jiangs  $178,533   $19,789 
Due to shareholders   143,528    152,382 
Due to a Director   4,237    961 
Total  $326,298   $173,132